Lantheus (NASDAQ:LNTH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a strong-buy rating in a research note released on Saturday morning.

A number of other research analysts also recently issued reports on the company. Citizens Jmp increased their price objective on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a report on Tuesday, February 24th. Truist Financial upped their price target on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, February 26th. Citigroup restated an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Finally, Mizuho lifted their price target on shares of Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $82.17.

Lantheus Trading Up 10.3%

Shares of NASDAQ:LNTH opened at $80.01 on Friday. The firm has a market cap of $5.17 billion, a price-to-earnings ratio of 23.74 and a beta of -0.11. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.29. The company’s fifty day simple moving average is $69.36 and its 200 day simple moving average is $61.12. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The firm had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts forecast that Lantheus will post 6.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently modified their holdings of the business. Elevation Point Wealth Partners LLC acquired a new stake in Lantheus in the 2nd quarter worth about $26,000. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus during the 2nd quarter worth approximately $36,000. Hantz Financial Services Inc. grew its position in shares of Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares in the last quarter. First Horizon Corp bought a new position in shares of Lantheus during the third quarter worth approximately $26,000. Finally, Smartleaf Asset Management LLC raised its position in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.